{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:07:53Z","timestamp":1771286873739,"version":"3.50.1"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Das lokalisierte Urothelkarzinom des oberen Harntrakts (UTUC) stellt aufgrund seiner biologischen Heterogenit\u00e4t und anatomischen Komplexit\u00e4t eine diagnostische Herausforderung dar. Eine fr\u00fchzeitige Erkennung und pr\u00e4zise Risikostratifizierung sind entscheidend f\u00fcr eine verbesserte Prognose. Die Kombination von Histologie, Urinzytologie und Biopsie spielt dabei eine zentrale Rolle. Die histopathologische Analyse soll eine Bestimmung des Tumorgrades erm\u00f6glichen, wobei die Unterscheidung zwischen Low- und High-Grade-Tumoren von Bedeutung ist. Die Urinzytologie hat eine hohe Sensitivit\u00e4t f\u00fcr High-Grade-Tumoren, aber eine eingeschr\u00e4nkte bei low grade. Molekulare Marker wie FGFR3- und TP53-Mutationen sowie eine Mikrosatelliteninstabilit\u00e4t (MSI) bei Lynch-Syndrom k\u00f6nnen zur Risikostratifizierung und Einsch\u00e4tzung des Tumorverhaltens beitragen. Die endoskopische Resektion stellt eine potenziell effektive, organerhaltende Therapie dar, insbesondere bei nicht-invasiven und Low-Grade-Tumoren. Trotz h\u00f6herer Rezidivraten im Vergleich zur radikalen Nephroureterektomie (RNU) kann sie eine wertvolle Option durch ihren organerhaltenden Ansatz f\u00fcr Patienten mit chronischer Niereninsuffizienz sein, erfordert jedoch eine engmaschige Nachsorge.<\/jats:p>","DOI":"10.1055\/a-2768-9305","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:10:29Z","timestamp":1769472629000},"page":"60-65","source":"Crossref","is-referenced-by-count":0,"title":["Urothelkarzinom des oberen Harntrakts \u2013 lokalisiert: Histopathologie, Molekulargenetik und klinische Besonderheiten"],"prefix":"10.1055","volume":"57","author":[{"given":"Veronika","family":"Bahlinger","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Maas","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[{"name":"Urology, Universit\u00e4tsklinikum Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"ref1","first-page":"123","article-title":"EAU guidelines on upper urinary tract urothelial carcinoma: 2024 update","volume":"85","author":"M Roupr\u00eat","year":"2024","journal-title":"Eur Urol"},{"key":"ref3","first-page":"684","article-title":"Prognostic factors and risk groups in upper urinary tract urothelial carcinoma","volume":"119","author":"SF Shariat","year":"2017","journal-title":"BJU Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0022-5347(05)67019-X","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last two decades","volume":"164","author":"JJ Munoz","year":"2000","journal-title":"J Urol"},{"issue":"S 1","key":"ref5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2022.12.001","article-title":"US Renal Data System. Annual data report 2022: epidemiology of kidney disease in the United States","volume":"79","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"ref6","first-page":"103","article-title":"Complications and long-term renal function after nephroureterectomy for upper tract urothelial carcinoma","volume":"61","author":"G Novara","year":"2012","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"AS Go","year":"2004","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrurol.2011.96","article-title":"Prognostic factors for upper urinary tract urothelial carcinoma","volume":"8","author":"TF Chromecki","year":"2011","journal-title":"Nat Rev Urol"},{"key":"ref9","first-page":"965","article-title":"Endoscopic management of upper tract urothelial carcinoma: long-term follow-up in a large cohort of patients","volume":"199","author":"L Villa","year":"2018","journal-title":"J Urol"},{"key":"ref10","first-page":"1234","article-title":"Pathology of upper tract urothelial carcinoma","volume":"139","author":"L Cheng","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"ref11","first-page":"150","article-title":"Histopathologic challenges in upper tract urothelial carcinoma","volume":"35","author":"F Soria","year":"2017","journal-title":"Urol Oncol"},{"key":"ref12","first-page":"89","article-title":"Impact of diagnostic ureteroscopy on histology in upper tract urothelial carcinoma","volume":"33","author":"T Seisen","year":"2015","journal-title":"World J Urol"},{"key":"ref13","first-page":"921","article-title":"Molecular classification of upper tract urothelial carcinoma","volume":"75","author":"F Audenet","year":"2019","journal-title":"Eur Urol"},{"key":"ref14","first-page":"3438","article-title":"Genomic characterization of upper tract urothelial carcinoma versus bladder cancer","volume":"33","author":"JP Sfakianos","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/ijc.29279","article-title":"TERT promoter mutations in urothelial carcinoma","volume":"136","author":"I Hosen","year":"2015","journal-title":"Int J Cancer"},{"key":"ref16","first-page":"272","article-title":"CDKN2A loss and progression of urothelial carcinoma of the upper tract","volume":"19","author":"A Lamy","year":"2006","journal-title":"Mod Pathol"},{"key":"ref17","first-page":"3450","article-title":"ERBB2 alterations in urothelial carcinoma","volume":"6","author":"J Kim","year":"2015","journal-title":"Oncotarget"},{"key":"ref18","first-page":"3914","article-title":"Mismatch repair gene defects in Lynch-associated upper tract urothelial carcinoma","volume":"17","author":"DK Crockett","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref19","first-page":"274","article-title":"Risks of upper tract urothelial carcinoma in Lynch syndrome carriers","volume":"105","author":"AK Win","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"ref20","first-page":"623","article-title":"Upper tract urothelial carcinoma and Lynch syndrome: clinical and molecular features","volume":"192","author":"SC Skeldon","year":"2014","journal-title":"J Urol"},{"key":"ref21","first-page":"575","article-title":"MSH2 and MSH6 mutations in Lynch-associated upper tract urothelial carcinoma","volume":"13","author":"S Haraldsdottir","year":"2014","journal-title":"Fam Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"A Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-5347(01)65273-X","article-title":"Diagnostic accuracy of ureteroscopic biopsy in upper tract urothelial carcinoma","volume":"157","author":"FX Keeley","year":"1997","journal-title":"J Urol"},{"key":"ref24","first-page":"491","article-title":"Limitations of ureteroscopic biopsy in the management of upper tract urothelial carcinoma","volume":"57","author":"A Breda","year":"2010","journal-title":"Eur Urol"},{"key":"ref25","first-page":"259","article-title":"Accuracy of ureteroscopic biopsy for upper tract urothelial carcinoma","volume":"29","author":"J Messer","year":"2011","journal-title":"Urol Oncol"},{"key":"ref26","first-page":"1027","article-title":"Urinary cytology in the diagnosis of upper tract urothelial carcinoma","volume":"29","author":"C Mian","year":"2016","journal-title":"Mod Pathol"},{"key":"ref27","first-page":"25","article-title":"Accuracy of urinary cytology for upper tract urothelial carcinoma","volume":"118","author":"F Brimo","year":"2010","journal-title":"Cancer Cytopathol"},{"key":"ref28","first-page":"532","article-title":"Molecular markers in the diagnosis of upper tract urothelial carcinoma","volume":"35","author":"F Descotes","year":"2017","journal-title":"Urol Oncol"},{"key":"ref29","first-page":"176","article-title":"Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert Bladder Cancer Monitor) for predicting tumour recurrence in NMIBC","volume":"127","author":"B Cowan","year":"2021","journal-title":"BJU Int"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fgene.2019.01237","article-title":"Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study","volume":"10","author":"R Batista","year":"2019","journal-title":"Front Genet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12894-018-0327-6","article-title":"Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician\u2013patient real-world data analysis (Cxbladder)","volume":"18","author":"T Lough","year":"2018","journal-title":"BMC Urol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Oncological outcomes following endoscopic management of upper tract urothelial carcinoma: a systematic review","volume":"110","author":"ML Cutress","year":"2012","journal-title":"BJU Int"},{"key":"ref33","first-page":"1059","article-title":"Predictors of recurrence after conservative management of upper tract urothelial carcinoma","volume":"70","author":"T Seisen","year":"2016","journal-title":"Eur Urol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2768-9305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:40:53Z","timestamp":1771285253000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2768-9305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":32,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2768-9305","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}